2023
Utilization and Outcomes of Primary Prevention Implantable Cardioverter‐Defibrillators in Patients With Hypertrophic Cardiomyopathy
Goldstein S, Kennedy K, Friedman D, Al‐Khatib S, Wang A. Utilization and Outcomes of Primary Prevention Implantable Cardioverter‐Defibrillators in Patients With Hypertrophic Cardiomyopathy. Journal Of The American Heart Association 2023, 12: e029293. PMID: 37586066, PMCID: PMC10492935, DOI: 10.1161/jaha.122.029293.Peer-Reviewed Original ResearchConceptsNew York Heart Association classPrimary prevention implantable cardioverter-defibrillatorHistory of nonsustained ventricular tachycardiaImplantable cardioverter-defibrillatorImplantable cardioverter-defibrillator utilizationNonsustained ventricular tachycardiaHypertrophic cardiomyopathyAssociation classVentricular tachycardiaOlder patientsCardioverter-defibrillatorLeft ventricular ejection fractionRisk factorsNational Cardiovascular Data Registry ICD RegistryFactors associated with mortalityImplantable cardioverter-defibrillator implantationAssociated with postdischarge mortalityVentricular ejection fractionPrevalence of risk factorsSudden cardiac deathPostdischarge hospitalizationAssociated with hospitalizationCenters for MedicareEjection fractionICD Registry
2020
Implantable Cardioverter Defibrillator Utilization and Mortality Among Patients ≥65 Years of Age With a Low Ejection Fraction After Coronary Revascularization
Goldstein S, Li S, Lu D, Matsouaka R, Rymer J, Fonarow G, de Lemos J, Peterson E, Pokorney S, Wang T, Al-Khatib S. Implantable Cardioverter Defibrillator Utilization and Mortality Among Patients ≥65 Years of Age With a Low Ejection Fraction After Coronary Revascularization. The American Journal Of Cardiology 2020, 138: 26-32. PMID: 33068540, DOI: 10.1016/j.amjcard.2020.09.056.Peer-Reviewed Original ResearchMeSH KeywordsAftercareAge FactorsAgedAged, 80 and overCardiologyCoronary Artery BypassDeath, Sudden, CardiacDefibrillators, ImplantableFemaleHeart FailureHumansMaleMedicareMortalityMyocardial InfarctionMyocardial RevascularizationPatient ReadmissionPercutaneous Coronary InterventionProportional Hazards ModelsSex FactorsStroke VolumeTachycardia, VentricularUnited StatesVentricular FibrillationConceptsImplantable cardioverter-defibrillator implantationImplantable cardioverter-defibrillatorIn-hospital ventricular arrhythmiasLow ejection fractionAssociated with ICD implantationEjection fractionVentricular arrhythmiasICD implantationCoronary revascularizationCABG-treated patientsPCI-treated patientsAssociated with lower mortalityCardiology follow-upIn-hospital revascularizationAll-cause mortalityAssociated with higher likelihoodICD utilizationHeart failure readmissionHeart failureYear of revascularizationCardioverter-defibrillatorRevascularization strategyMedicare claimsRevascularizationPatientsIMPLANTABLE CARDIOVERTER-DEFIBRILLATOR (ICD) UTILIZATION AMONG OLDER PATIENTS WITH LOW EJECTION FRACTION FOLLOWING CORONARY REVASCULARIZATION FOR MYOCARDIAL INFARCTION
Goldstein S, Lu D, Matsouaka R, Wang T, Rymer J, Pokorney S, Al-Khatib S. IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR (ICD) UTILIZATION AMONG OLDER PATIENTS WITH LOW EJECTION FRACTION FOLLOWING CORONARY REVASCULARIZATION FOR MYOCARDIAL INFARCTION. Journal Of The American College Of Cardiology 2020, 75: 379. DOI: 10.1016/s0735-1097(20)31006-8.Peer-Reviewed Original ResearchImplantable cardioverter-defibrillator
2019
Complications involving the subcutaneous implantable cardioverter-defibrillator: Lessons learned from MAUDE
Zeitler E, Friedman D, Loring Z, Campbell K, Goldstein S, Wegermann Z, Schutz J, Smith N, Black-Maier E, Al-Khatib S, Piccini J. Complications involving the subcutaneous implantable cardioverter-defibrillator: Lessons learned from MAUDE. Heart Rhythm 2019, 17: 447-454. PMID: 31561032, PMCID: PMC7519585, DOI: 10.1016/j.hrthm.2019.09.024.Peer-Reviewed Original ResearchConceptsSubcutaneous implantable cardioverter-defibrillatorS-ICD complicationsImplantable cardioverter-defibrillatorS-ICDInappropriate shocksCardioverter-defibrillatorSystem removalLow rate of complicationsProcedure-related complicationsRate of complicationsFood and Drug Administration's ManufacturerManufacturer and User Facility Device ExperienceUser Facility Device ExperiencePatient selectionFollow-upComplicationsTransvenous devicesVentricular fibrillationDevice-device interactionsClinical experiencePatientsDefibrillation failureImplantation techniqueSystem reprogrammingSystem revision
2017
The Use of Implantable Cardioverter-defibrillators in the Prevention of Sudden Cardiac Death: A Focus on Congenital Heart Disease and Inherited Arrhythmia Syndromes
Goldstein S, Ward C, Al-Khatib S. The Use of Implantable Cardioverter-defibrillators in the Prevention of Sudden Cardiac Death: A Focus on Congenital Heart Disease and Inherited Arrhythmia Syndromes. Journal Of Innovations In Cardiac Rhythm Management 2017, 9: 2996-3005. PMID: 32494470, PMCID: PMC7252881, DOI: 10.19102/icrm.2018.090103.Peer-Reviewed Original ResearchCongenital heart diseaseInherited arrhythmia syndromesSudden cardiac deathArrhythmia syndromesCardiac deathIncreased risk of sudden cardiac deathPrevention of sudden cardiac deathRisk of sudden cardiac deathHeart diseaseImplantable cardioverter-defibrillator (ICDCardioverter-defibrillator (ICDRisk stratification methodsNon-randomized studiesImplantable cardioverter-defibrillatorRandomized clinical trialsCardioverter-defibrillatorClinical trialsIncreased riskPatientsSyndromeDiseaseImplantationStratification methodICDDeath